Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a randomized double-blind study of TAS5315 in chronic spontaneous urticaria
jRCT2031210693Phase 2Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of TAS5315 in chronic idiopathic urticaria (CIU), sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoint: Change in UAS7 at week 12. Started Jun 2022; status: completed.
02
Drugs
TAS5315
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on jRCT2031210693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210693.